论文部分内容阅读
目的探讨肝动脉化疗栓塞(TACE)联合重组人血管内皮抑制素介入治疗原发性肝细胞癌(HCC)的临床疗效。方法:将52例HCC患者随机分为观察组和对照组各26例,观察组给予TACE联合重组人血管内皮抑制素介入治疗,对照组单纯给予TACE治疗,比较两组的不良反应、临床疗效及治疗前后血液甲胎蛋白(AFP)水平、肝外转移等情况。结果:治疗后两组的血液AFP水平、不良反应发生率等比较,差异无统计学意义(P>0.05);观察组总有效率明显高于对照组,差异有统计学意义(P<0.05);术后1年的肝外转移发生率明显低于对照组,差异有统计学意义(P<0.01)。结论:TACE联合重组人血管内皮抑制素介入治疗HCC能提高疗效,有效地减少肿瘤肝外转移,安全有效。
Objective To investigate the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with recombinant human endostatin in the treatment of primary hepatocellular carcinoma (HCC). Methods: Totally 52 HCC patients were randomly divided into observation group and control group, with 26 patients in observation group and TACE combined with recombinant human endostatin. The control group was treated with TACE alone. The adverse reaction, clinical efficacy and clinical efficacy were compared between the two groups Before and after treatment of blood AFP (AFP) levels, extrahepatic metastasis and so on. Results: There was no significant difference in blood AFP level and incidence of adverse reactions between the two groups after treatment (P> 0.05). The total effective rate in the observation group was significantly higher than that in the control group (P <0.05) The incidence of extrahepatic metastasis at 1 year after operation was significantly lower than that of the control group (P <0.01). Conclusion: TACE combined with recombinant human endostatin in interventional therapy for HCC can improve the curative effect and effectively reduce the extrahepatic metastasis of tumor, which is safe and effective.